Prelude's Military Families Month campaign comes on the heels of the Department ... and they continue to lead the industry by building on these technologies by through development, research and ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated ... controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

Prelude Therapeutics Incorporated (PRLD) has been on a downward spiral lately with significant selling pressure. After ...

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

Prelude Therapeutics ( (PRLD) ) has provided an announcement. Prelude Therapeutics announced its third quarter 2024 financial results, ...

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS ...

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...